Luye Pharma Group Ltd.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LYPHF research report →
Companywww.luye.cn
Luye Pharma Group Ltd. , an investment holding company, develops, produces, markets, and sells pharmaceutical products worldwide. The company offers Lipusu for ovarian and breast cancer; CMNa, a chemical sensitizer for cancer radiotherapy; Tiandida for ovarian or non-small cell lung cancer; Boyounuo, an injection for the treatment of various types of cancers and other solid tumors; and Xuezhikang, a lipid regulating drug for the treatment of hypercholesterolaemia.
- CEO
- Dian Bo Liu
- IPO
- 2021
- Employees
- 5,150
- HQ
- Yantai, CN
Price Chart
Valuation
- Market Cap
- $1.31B
- P/E
- 12.78
- P/S
- 1.24
- P/B
- 0.49
- EV/EBITDA
- 6.77
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 65.99%
- Op Margin
- 19.70%
- Net Margin
- 9.81%
- ROE
- 4.02%
- ROIC
- 3.13%
Growth & Income
- Revenue
- $6.15B · 1.39%
- Net Income
- $602.78M · 27.74%
- EPS
- $0.15 · 757.14%
- Op Income
- $1.21B
- FCF YoY
- 150.65%
Performance & Tape
- 52W High
- $0.40
- 52W Low
- $0.27
- 50D MA
- $0.36
- 200D MA
- $0.34
- Beta
- 0.92
- Avg Volume
- 19.67K
Get TickerSpark's AI analysis on LYPHF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our LYPHF Coverage
We haven't published any research on LYPHF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate LYPHF Report →